At the news
? BULLISHIMPACT 9/10 8-K filed Mar 31, 2026 at 16:05 ET
Omeros reported a massive earnings beat for Q4 2025, driven by a $237.6M gain from the zaltenibart sale to Novo Nordisk and FDA approval of YARTEMLEA. The company turned profitable with GAAP net income of $86.5M ($1.22/share) versus a $31.4M loss in the prior year, while non-GAAP adjusted EPS hit $3.14, crushing consensus. Cash rose to $171.8M and debt was slashed by 47%.
- Net income for Q4 2025 was $86.5M ($1.22/share), compared to a net loss of $31.4M ($0.54/share) in Q4 2024
- Non-GAAP adjusted net income was $222.5M ($3.14/share), a 670.9% beat vs. consensus of $-0.55
- Recognized $237.6M in net proceeds from the sale of zaltenibart to Novo Nordisk
- FDA approved YARTEMLEA for TA-TMA, with commercial launch underway in January 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access